IGF2BP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL11593721	0.81	1/20
SCHEMBL11339738	0.72	1/20
SCHEMBL2272429	0.71	1/20
SCHEMBL2276941	0.68	1/20
SCHEMBL6676510	0.62	1/20
SCHEMBL7125490	0.62	1/20
SCHEMBL2293270	0.62	1/20
SCHEMBL421010	0.62	1/20
SCHEMBL6353351	0.62	1/20
SCHEMBL14075221	0.62	1/20
SCHEMBL2269841	0.61	1/20
SCHEMBL2274009	0.61	1/20
SCHEMBL5446055	0.61	1/20
SCHEMBL14075299	0.60	1/20
SCHEMBL3959658	0.60	1/20
SCHEMBL17627523	0.60	1/20
SCHEMBL563078	0.60	1/20
SCHEMBL1337733	0.59	1/20
SCHEMBL16102033	0.59	1/20
SCHEMBL1954779	0.59	1/20

Clinical trials — most relevant to IGF2BP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer	PHASE4	WITHDRAWN
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Pappalysin 2 (PAPP-A2) Enzyme Replacement	PHASE1	COMPLETED
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate	PHASE1	COMPLETED
Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers	PHASE1	COMPLETED
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma	PHASE1	COMPLETED
A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome	PHASE1	COMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED
Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer	nan	COMPLETED
Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer	nan	UNKNOWN
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)	nan	COMPLETED
IGF and Other Neurotrophic Factors in Patients With Dementia	nan	COMPLETED
Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation	nan	UNKNOWN
Serum IGF-1 and IGF-1Ec in Malignancy Assessment	nan	ACTIVE_NOT_RECRUITING
Role of LncRNA H19 in The Regulation of IGF-1R Expression	nan	COMPLETED
Adipocytokines in Endometrial Cancer	nan	COMPLETED
Molecular Quantification of Insulin mRNA	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Advancing Early Bone Health: New Frontiers for Osteoporosis Prevention	nan	ACTIVE_NOT_RECRUITING
Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt	nan	NOT_YET_RECRUITING
Brown Seaweed Extract on Glycemic Control and Body Weight	nan	COMPLETED
Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans	nan	COMPLETED
Effect of Insulin Sensitization on IGF-1 Response to Growth Hormone in SGA Children	nan	UNKNOWN
Short-Term Fasting Before Chemotherapy in Treating Patients With Cancer	nan	COMPLETED
Maternal Hypertriglyceridaemia Study	nan	UNKNOWN
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer	nan	UNKNOWN
Metabolic and Inflammatory Responses to Hemodialysis and the Effect of a Meal	nan	COMPLETED
Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle	nan	COMPLETED
Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IGF2BP2 binder may also engage these)

Protein	Name	Similarity
Q5SF07	—	1.000	Q5SF07 →
Q8CGX0	—	1.000	Q8CGX0 →
IGF2BP3	Insulin-like growth factor 2 mRNA-binding protein 3	1.000	landscape →
O73932	—	1.000	O73932 →
O57526	—	1.000	O57526 →
Q5RB68	—	0.998	Q5RB68 →
Q08CK7	—	0.996	Q08CK7 →
Q5ZLP8	—	0.995	Q5ZLP8 →
Q9PW80	—	0.994	Q9PW80 →
O42254	—	0.993	O42254 →
Q9CPN8	—	0.993	Q9CPN8 →
O88477	—	0.991	O88477 →
IGF2BP1	Insulin-like growth factor 2 mRNA-binding protein 1	0.988	landscape →
Q9LZ82	—	0.983	Q9LZ82 →
Q756R8	—	0.982	Q756R8 →
C5DIR2	—	0.981	C5DIR2 →
Q4VXU2	—	0.981	Q4VXU2 →
P90978	—	0.980	P90978 →
Q9NQ94	—	0.980	Q9NQ94 →
Q6DEY7	—	0.980	Q6DEY7 →
Q7TMK9	—	0.978	Q7TMK9 →
SYNCRIP	Heterogeneous nuclear ribonucleoprotein Q	0.978	landscape →
Q3T0D0	—	0.978	Q3T0D0 →
Q54BM2	—	0.978	Q54BM2 →
Q05196	—	0.978	Q05196 →
Q9H361	—	0.977	Q9H361 →
Q8GZ26	—	0.977	Q8GZ26 →
P38151	—	0.977	P38151 →
Q5R5H8	—	0.977	Q5R5H8 →
Q5R8F7	—	0.977	Q5R8F7 →